JP2009540001A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009540001A5 JP2009540001A5 JP2009515517A JP2009515517A JP2009540001A5 JP 2009540001 A5 JP2009540001 A5 JP 2009540001A5 JP 2009515517 A JP2009515517 A JP 2009515517A JP 2009515517 A JP2009515517 A JP 2009515517A JP 2009540001 A5 JP2009540001 A5 JP 2009540001A5
- Authority
- JP
- Japan
- Prior art keywords
- polysorbate
- formulation
- vegf antagonist
- sodium phosphate
- phosphate buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 16
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 16
- 239000005557 antagonist Substances 0.000 claims description 12
- 238000009472 formulation Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 239000012931 lyophilized formulation Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 12
- 229950008882 polysorbate Drugs 0.000 claims 7
- 229920000136 polysorbate Polymers 0.000 claims 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 6
- 239000011780 sodium chloride Substances 0.000 claims 6
- 239000012064 sodium phosphate buffer Substances 0.000 claims 6
- 239000002202 Polyethylene glycol Substances 0.000 claims 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 5
- 229930006000 Sucrose Natural products 0.000 claims 5
- 229920001223 polyethylene glycol Polymers 0.000 claims 5
- 239000005720 sucrose Substances 0.000 claims 5
- 239000007951 isotonicity adjuster Substances 0.000 claims 3
- 239000003381 stabilizer Substances 0.000 claims 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 239000000600 sorbitol Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000006184 cosolvent Substances 0.000 claims 1
- 239000001103 potassium chloride Substances 0.000 claims 1
- 235000011164 potassium chloride Nutrition 0.000 claims 1
- 229940071643 prefilled syringe Drugs 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 229940076372 protein antagonist Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81448406P | 2006-06-16 | 2006-06-16 | |
| US60/814,484 | 2006-06-16 | ||
| PCT/US2007/014085 WO2007149334A2 (en) | 2006-06-16 | 2007-06-14 | Vegf antagonist formulations suitable for intravitreal administration |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013040234A Division JP5597271B2 (ja) | 2006-06-16 | 2013-03-01 | 硝子体内投与に適したｖｅｇｆアンタゴニスト製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009540001A JP2009540001A (ja) | 2009-11-19 |
| JP2009540001A5 true JP2009540001A5 (enExample) | 2013-02-07 |
| JP5216002B2 JP5216002B2 (ja) | 2013-06-19 |
Family
ID=38834013
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009515517A Active JP5216002B2 (ja) | 2006-06-16 | 2007-06-14 | 硝子体内投与に適したｖｅｇｆアンタゴニスト製剤 |
| JP2013040234A Active JP5597271B2 (ja) | 2006-06-16 | 2013-03-01 | 硝子体内投与に適したｖｅｇｆアンタゴニスト製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013040234A Active JP5597271B2 (ja) | 2006-06-16 | 2013-03-01 | 硝子体内投与に適したｖｅｇｆアンタゴニスト製剤 |
Country Status (22)
| Country | Link |
|---|---|
| US (16) | US7608261B2 (enExample) |
| EP (4) | EP2944306B1 (enExample) |
| JP (2) | JP5216002B2 (enExample) |
| KR (1) | KR101406811B1 (enExample) |
| CN (2) | CN104434770A (enExample) |
| AU (1) | AU2007261536C1 (enExample) |
| BR (1) | BRPI0713749B8 (enExample) |
| CA (1) | CA2654510C (enExample) |
| CY (2) | CY1114244T1 (enExample) |
| DK (2) | DK2364691T3 (enExample) |
| ES (2) | ES2406764T3 (enExample) |
| HK (1) | HK1204580A1 (enExample) |
| HU (2) | HUE018715T2 (enExample) |
| IL (1) | IL195788A (enExample) |
| LT (1) | LT2944306T (enExample) |
| MX (1) | MX2008016124A (enExample) |
| PL (2) | PL2364691T3 (enExample) |
| PT (2) | PT2944306T (enExample) |
| RU (1) | RU2432155C3 (enExample) |
| SI (2) | SI2364691T1 (enExample) |
| WO (1) | WO2007149334A2 (enExample) |
| ZA (1) | ZA200809827B (enExample) |
Families Citing this family (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2281885A1 (en) * | 2003-08-27 | 2011-02-09 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
| ES2633574T3 (es) | 2005-03-25 | 2017-09-22 | Regeneron Pharmaceuticals, Inc. | Formulaciones de antagonistas de VEGF |
| AU2007237096C1 (en) | 2006-04-07 | 2012-12-13 | EyePoint Pharmaceuticals, Inc. | Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof |
| PT2944306T (pt) | 2006-06-16 | 2021-02-15 | Regeneron Pharma | Formulações antagonistas de vegf adequadas para administração intravitreal |
| PL2319357T3 (pl) | 2007-01-18 | 2013-08-30 | Eveready Battery Inc | System do golenia z ogniwem wytwarzającym gaz |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US8956600B2 (en) * | 2009-08-10 | 2015-02-17 | Taiwan Liposome Co. Ltd. | Ophthalmic drug delivery system containing phospholipid and cholesterol |
| AU2011312191B2 (en) | 2010-10-06 | 2015-07-02 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies |
| BR112013017752A8 (pt) | 2011-01-13 | 2018-01-09 | Regeneron Pharma | uso de um antagonista do vegf e formulação farmacêutica |
| CN110711248A (zh) | 2011-01-28 | 2020-01-21 | 赛诺菲生物技术公司 | 包含针对pcsk9的人抗体的药物组合物 |
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| ES2992345T3 (es) | 2011-09-16 | 2024-12-11 | Regeneron Pharma | Métodos para reducir los niveles de lipoproteína(a) mediante la administración de un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9) |
| US20130095065A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for Treating Vascular Leak Syndrome and Cancer |
| ES2810003T3 (es) | 2011-11-18 | 2021-03-08 | Regeneron Pharma | Micropartícula que contiene proteína terapéutica recubierta con polímero biodegradable para uso médico |
| CN107115294B (zh) * | 2012-01-19 | 2019-10-18 | 北京康弘生物医药有限公司 | 一种含有vegf拮抗剂的滴眼液 |
| MY164611A (en) | 2012-01-23 | 2018-01-30 | Regeneron Pharma | Stabilized formulations containing anti-ang2 antibodies |
| AR092325A1 (es) | 2012-05-31 | 2015-04-15 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit |
| US20130323242A1 (en) * | 2012-06-01 | 2013-12-05 | Ophthotech Corp. | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
| LT3679922T (lt) | 2012-06-01 | 2021-10-25 | Novartis Ag | Švirkštas |
| EP2854844A4 (en) * | 2012-06-01 | 2016-11-23 | Ophthotech Corp | COMPOSITIONS COMPRISING AN ANTI-PDGF APTAMER AND A VEGF ANTAGONIST |
| AU2012101677B4 (en) * | 2012-07-03 | 2012-12-20 | Novartis Ag | Device |
| JOP20200175A1 (ar) * | 2012-07-03 | 2017-06-16 | Novartis Ag | حقنة |
| AU2013100360B4 (en) * | 2012-07-03 | 2013-05-16 | Novartis Ag | Device |
| AU2013100070B4 (en) * | 2012-07-03 | 2013-04-04 | Novartis Ag | Use of device |
| US8922746B2 (en) | 2012-08-06 | 2014-12-30 | Shenzhen China Star Optoelectronics Technology Co., Ltd | Liquid crystal injection device and liquid crystal container thereof |
| UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| MY170528A (en) | 2013-02-18 | 2019-08-09 | Vegenics Pty Ltd | Vegfr-3 ligand binding molecules and uses thereof |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| AU2014274844B2 (en) | 2013-06-07 | 2019-11-28 | Regeneron Pharmaceuticals, Inc. | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 |
| EP3019243A4 (en) | 2013-07-12 | 2017-03-15 | Ophthotech Corporation | Methods for treating or preventing ophthalmological conditions |
| US10273298B2 (en) | 2013-07-23 | 2019-04-30 | Novaliq Gmbh | Stabilized antibody compositions |
| MX2016001854A (es) | 2013-08-12 | 2016-09-06 | Genentech Inc | Composiciones y metodo para tratar condiciones asociadas con el complemento. |
| CN103622961B (zh) * | 2013-09-06 | 2016-03-02 | 武汉光谷百桥国际生物科技有限公司 | 一种非肽类缓激肽b2受体激动剂在促进毛发生长方面的应用 |
| EP3068803B1 (en) | 2013-11-12 | 2021-01-20 | Sanofi Biotechnology | Dosing regimens for use with pcsk9 inhibitors |
| WO2015071348A1 (en) * | 2013-11-18 | 2015-05-21 | Formycon Ag | Pharmaceutical composition of an anti-vegf antibody |
| EA201692109A1 (ru) | 2014-05-01 | 2017-03-31 | Дженентек, Инк. | Варианты антител к фактору d и их применение |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| RU2735521C2 (ru) | 2014-07-16 | 2020-11-03 | Санофи Байотекнолоджи | Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh) |
| PT3170005T (pt) | 2014-07-18 | 2019-07-16 | Sanofi Sa | Método para a previsão do resultado de um tratamento com aflibercept de um paciente suspeito de sofrer de um cancro |
| CN104940926B (zh) | 2014-09-25 | 2017-09-22 | 信达生物制药(苏州)有限公司 | 重组融合蛋白制剂 |
| TW201628649A (zh) | 2014-10-09 | 2016-08-16 | 再生元醫藥公司 | 減少醫藥調配物中微可見顆粒之方法 |
| TWI738632B (zh) | 2014-11-07 | 2021-09-11 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| US20160144025A1 (en) * | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| MX2017009759A (es) | 2015-01-28 | 2017-10-27 | Pfizer | Formulacion de anticuerpo del anti-factor de crecimiento endotelial vascular (vegf) acuosa estable. |
| KR101808234B1 (ko) | 2015-06-23 | 2017-12-12 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제 |
| US10772956B2 (en) | 2015-08-18 | 2020-09-15 | Regeneron Pharmaceuticals, Inc. | Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab |
| CN110403923B (zh) | 2015-09-30 | 2021-09-21 | 诺瓦利克有限责任公司 | 半氟化化合物和其组合物 |
| AU2016340072B2 (en) * | 2015-10-16 | 2021-10-28 | Regeneron Pharmaceuticals, Inc. | Stable protein compositions |
| JP2018536650A (ja) | 2015-10-30 | 2018-12-13 | ジェネンテック， インコーポレイテッド | 抗ｄ因子抗体変異体コンジュゲート及びその使用 |
| WO2017075173A2 (en) | 2015-10-30 | 2017-05-04 | Genentech, Inc. | Anti-factor d antibodies and conjugates |
| RU2734958C2 (ru) | 2015-11-18 | 2020-10-26 | Формикон Аг | Предварительно заполненная фармацевтическая упаковка, содержащая жидкий состав на основе антагониста vegf |
| CA3005132A1 (en) | 2015-11-18 | 2017-05-26 | Sio2 Medical Products, Inc. | Coated syringe for ophthalmic formulations containing a vegf antagonist |
| CA3007276C (en) | 2015-12-03 | 2021-12-28 | Regeneron Pharmaceuticals, Inc. | Use of vegf inhibitor to treat macular degeneration in a patient population |
| ES2981791T3 (es) * | 2015-12-16 | 2024-10-10 | Regeneron Pharma | Composiciones y métodos para fabricar micropartículas de proteína |
| AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
| AU2017213103B2 (en) * | 2016-01-26 | 2022-08-11 | Formycon Ag | Liquid formulation of a VEGF antagonist |
| GB201612317D0 (en) | 2016-07-15 | 2016-08-31 | Philogen Spa | Antibody compositions |
| IL322404A (en) | 2016-07-29 | 2025-09-01 | Regeneron Pharma | Assembly line with built-in electronic visual inspection |
| US11020686B2 (en) | 2016-08-16 | 2021-06-01 | Regeneron Pharmaceuticals, Inc. | Methods for quantitating individual antibodies from a mixture |
| US11692027B2 (en) | 2016-09-28 | 2023-07-04 | Board Of Regents, The University Of Texas System | Antibody and protein therapeutic formulations and uses thereof |
| BR112019006689A2 (pt) | 2016-10-25 | 2019-06-25 | Regeneron Pharma | métodos e sistemas para análise de dados de cromatografia |
| JP7116059B2 (ja) * | 2016-11-21 | 2022-08-09 | ジャスト－エヴォテック バイオロジックス、インコーポレイテッド | アフリベルセプト製剤及びその使用 |
| US20180207293A1 (en) * | 2017-01-25 | 2018-07-26 | 2C Tech Corp. | Nanoparticles for sustained ophthalmic drug delivery and methods of use |
| KR101861163B1 (ko) * | 2017-04-26 | 2018-05-25 | 삼천당제약주식회사 | 안과용 약학 조성물 |
| JP7161494B2 (ja) | 2017-05-06 | 2022-10-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ａｐｌｎｒアンタゴニストおよびｖｅｇｆ阻害剤によって眼疾患を治療する方法 |
| WO2019020777A1 (en) | 2017-07-26 | 2019-01-31 | Formycon Ag | LIQUID FORMULATION OF A VEGF ANTAGONIST |
| MA50174A (fr) | 2017-09-18 | 2020-07-29 | Amgen Inc | Formules de protéines de fusion vegfr-fc |
| US12042538B2 (en) | 2017-09-19 | 2024-07-23 | Regeneron Pharmaceuticals, Inc. | Methods of reducing particle formation and compositions formed thereby |
| MA50908A (fr) | 2017-11-17 | 2020-09-23 | Amgen Inc | Formulations de protéines de fusion vegfr-fc |
| JP7183268B2 (ja) | 2017-11-20 | 2022-12-05 | ジャスト－エヴォテック バイオロジックス、インコーポレイテッド | 等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用 |
| EP3716992B1 (en) | 2017-11-30 | 2022-08-10 | Regeneron Pharmaceuticals, Inc. | Use of a vegf antagonist to treat angiogenic eye disorders |
| WO2019118187A1 (en) | 2017-12-13 | 2019-06-20 | Regeneron Pharmaceuticals, Inc. | Devices and systems for chromatography column bed support management and related methods |
| MA51162A (fr) | 2017-12-15 | 2020-10-21 | Apellis Pharmaceuticals Inc | Schémas posologiques et compositions et procédés associés |
| CA3189025A1 (en) * | 2017-12-22 | 2019-06-27 | Samsung Bioepis Co., Ltd. | Liquid composition comprising vegf antagonist |
| SG11202007130RA (en) | 2018-01-26 | 2020-08-28 | Univ California | Methods and compositions for treatment of angiogenic disorders using anti-vegf agents |
| CN112203679A (zh) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
| US11426446B2 (en) | 2018-03-08 | 2022-08-30 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| WO2019173767A1 (en) | 2018-03-08 | 2019-09-12 | Coherus Biosciences Inc. | Stable aqueous formulations of aflibercept |
| CA3094721A1 (en) * | 2018-04-05 | 2019-10-10 | Tarveda Therapeutics, Inc. | Pharmaceutical compositions with reduced tert-butanol levels |
| JP2021522219A (ja) | 2018-04-27 | 2021-08-30 | ノバリック ゲーエムベーハー | 緑内障の治療のためのタフルプロストを含む眼科用組成物 |
| TWI814812B (zh) | 2018-05-02 | 2023-09-11 | 美商里珍納龍藥品有限公司 | 用於評估生化過濾器的適合性的方法 |
| BR112020022610A2 (pt) | 2018-05-10 | 2021-02-09 | Regeneron Pharmaceuticals, Inc. | proteína de fusão de receptor de vegf de alta concentração que contém formulações |
| US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
| TWI853823B (zh) | 2018-07-02 | 2024-09-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
| JP7695187B2 (ja) | 2018-09-24 | 2025-06-18 | アイポイント ファーマシューティカルズ， インコーポレイテッド | ＨＰＴＰ－β（ＶＥ－ＰＴＰ）およびＶＥＧＦを標的にする多特異性抗体 |
| US20210353713A1 (en) | 2018-10-26 | 2021-11-18 | Amgen Inc. | Formulations comprising a tris buffer and a protein |
| WO2020109343A1 (en) | 2018-11-29 | 2020-06-04 | F. Hoffmann-La Roche Ag | Combination therapy for treatment of macular degeneration |
| US12397039B2 (en) | 2019-02-13 | 2025-08-26 | Novaliq Gmbh | Compositions and methods for the treatment of ocular neovascularization |
| KR102286892B1 (ko) * | 2019-07-08 | 2021-08-06 | 삼천당제약주식회사 | 안과용 단백질 제제의 정제방법 |
| AU2020320222A1 (en) * | 2019-08-01 | 2022-03-03 | Gennova Biopharmaceuticals Limited | Opthalmic composition of Bevacizumab |
| WO2021050687A1 (en) | 2019-09-10 | 2021-03-18 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| CA3150482A1 (en) | 2019-09-16 | 2021-03-25 | Amgen Inc. | Method for external sterilization of drug delivery device |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CA3168512A1 (en) | 2019-11-25 | 2021-06-03 | Napoleone Ferrara | Long-acting vegf inhibitors for intraocular neovascularization |
| US11186625B2 (en) | 2019-12-06 | 2021-11-30 | Regeneran Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
| AU2021268026A1 (en) | 2020-05-08 | 2023-01-19 | Regeneron Pharmaceuticals, Inc. | VEGF traps and mini-traps and methods for treating ocular disorders and cancer |
| WO2021231463A1 (en) | 2020-05-11 | 2021-11-18 | Regeneron Pharmaceuticals, Inc. | Viral clearance by low ph hold |
| US20230270670A1 (en) | 2020-07-24 | 2023-08-31 | Pangen Biotech Inc. | Ophthalmic liquid composition |
| CN116096357A (zh) * | 2020-07-31 | 2023-05-09 | 赛特瑞恩股份有限公司 | 稳定的药物制剂 |
| CN112245569B (zh) * | 2020-11-18 | 2024-05-28 | 通化东宝药业股份有限公司 | 一种稳定的阿柏西普制剂及其制备方法 |
| KR102720956B1 (ko) * | 2020-12-15 | 2024-10-24 | 삼천당제약주식회사 | 안과용 제형을 포함하는 시린지 |
| US12350374B2 (en) | 2020-12-17 | 2025-07-08 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
| WO2023153535A1 (ko) * | 2022-02-09 | 2023-08-17 | 삼천당제약주식회사 | 안과용 제형을 포함하는 시린지 |
| US11723955B1 (en) * | 2022-05-13 | 2023-08-15 | Allgenesis Biotherapeutics Inc. | VEGFR fusion protein pharmaceutical composition |
| WO2025176843A1 (en) | 2024-02-21 | 2025-08-28 | Ags Therapeutics Sas | Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof |
| US12240888B1 (en) | 2024-04-29 | 2025-03-04 | QILU Pharmaceutical, Co., Ltd. | Composition comprising aflibercept and a variant thereof, and related methods and uses |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1046492A (en) | 1907-11-14 | 1912-12-10 | Walter Chisholm Ranson | Flushing apparatus. |
| WO1989011298A1 (en) | 1988-05-27 | 1989-11-30 | Centocor, Inc. | Formulation for antibody reagents |
| AU2309692A (en) | 1991-07-03 | 1993-02-11 | Cryolife, Inc. | Method for stabilization of biomaterials |
| EP0638091B1 (en) | 1992-04-30 | 2005-12-07 | Probitas Pharma Inc. | Improved solubilization and stabilization of factor viii complex |
| SK282483B6 (sk) | 1992-10-02 | 2002-02-05 | Genetics Institute, Inc. | Stabilná kompozícia koagulačného faktora VIII, spôsob jej prípravy a stabilizácie |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| GB9410534D0 (en) | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | Improvements in or relating to growth factor inhibitors |
| US5656730A (en) | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
| DK1516628T3 (da) * | 1995-07-27 | 2013-09-08 | Genentech Inc | Stabil, isotonisk lyofiliseret proteinformulering |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| JPH09154588A (ja) | 1995-10-07 | 1997-06-17 | Toagosei Co Ltd | Ｖｅｇｆ結合性ポリペプチド |
| US5770700A (en) | 1996-01-25 | 1998-06-23 | Genetics Institute, Inc. | Liquid factor IX formulations |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
| US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| JPH10273450A (ja) * | 1997-03-27 | 1998-10-13 | Toagosei Co Ltd | 眼内血管新生性疾患治療薬 |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| ES2273415T3 (es) | 1997-04-07 | 2007-05-01 | Genentech, Inc. | Anticuerpos anti-vegf. |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| JPH1180024A (ja) | 1997-09-12 | 1999-03-23 | Toagosei Co Ltd | 角膜血管新生阻害剤 |
| US6436897B2 (en) | 1998-06-01 | 2002-08-20 | Celtrix Pharmaceuticals, Inc. | Pharmaceutical formulations for IGF/IGFBP |
| US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| DE60041367D1 (de) | 1999-04-16 | 2009-02-26 | Genentech Inc | Vaskuläre Endothelzellen Wachstumsfaktor (VEGF) Varianten und dessen Verwendungen |
| MXPA01010891A (es) | 1999-04-28 | 2002-11-07 | Univ Texas | Composiciones y metodos para el tratamiento contra el cancer mediante la inhibicion selectiva del factor de crecimiento endotelial vascular (vegf). |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| BRPI0011407B8 (pt) | 1999-06-08 | 2021-05-25 | Regeneron Pharma | molécula de ácido nucléico quimérica, polipeptídeo de fusão, vetor de expressão, sistema de vetor hospedeiro, e, métodos de produzir um polipeptídeo de fusão |
| US7306799B2 (en) | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
| US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| US6833349B2 (en) | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US7303746B2 (en) | 1999-06-08 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with modified chimeric polypeptides |
| US7001892B1 (en) | 1999-06-11 | 2006-02-21 | Purdue Research Foundation | Pharmaceutical materials and methods for their preparation and use |
| US6777429B1 (en) | 1999-07-23 | 2004-08-17 | Novartis Ag | Ophthalmic composition |
| ES2332402T5 (es) | 2000-10-12 | 2018-05-14 | Genentech, Inc. | Formulaciones de proteína concentradas de viscosidad reducida |
| RU2177801C1 (ru) * | 2001-01-25 | 2002-01-10 | Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" | Средство, ингибирующее ангиогенез при заболеваниях органа зрения |
| GB0113179D0 (en) | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
| KR20040019034A (ko) | 2001-07-06 | 2004-03-04 | 수캄포 아게 | 인터루킨 2 억제제 및 항미생물제를 포함하는 국소 투여용조성물 |
| JP4317010B2 (ja) | 2001-07-25 | 2009-08-19 | ピーディーエル バイオファーマ，インコーポレイティド | ＩｇＧ抗体の安定な凍結乾燥医薬製剤 |
| ATE556591T1 (de) | 2001-11-08 | 2012-05-15 | Abbott Biotherapeutics Corp | Stabile pharmazeutische flüssigformulierung von igg-antikörpern |
| EA006746B1 (ru) * | 2001-11-09 | 2006-04-28 | Айтек Фармасьютикалз | Способы лечения глазных неоваскулярных заболеваний |
| EP1478394B1 (en) | 2002-02-27 | 2008-07-30 | Immunex Corporation | Stabilized TNFR-Fc composition comprising arginine |
| DK1608685T3 (da) | 2003-03-28 | 2007-06-11 | Regeneron Pharma | VEGF antagonister til behandlingen af diabetes |
| HRP20050934B1 (hr) * | 2003-04-04 | 2014-09-26 | Genentech, Inc. | Formulacije s visokom koncentracijom antitijela i proteina |
| WO2004103159A2 (en) | 2003-05-14 | 2004-12-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for modulating endometrium |
| JP2007529418A (ja) | 2003-05-28 | 2007-10-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｖｅｇｆアンタゴニストの使用による角膜移植拒絶を処置する方法 |
| RS20150135A1 (sr) | 2003-05-30 | 2015-08-31 | Genentech Inc. | Tretman sa anti-vegf antitelima |
| US7354578B2 (en) | 2003-06-06 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Method of tumor regression with VEGF inhibitors |
| AR046510A1 (es) * | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| WO2005016369A1 (en) | 2003-08-06 | 2005-02-24 | Regeneron Pharmaceuticals, Inc. | Use of a vegf antagonist in combination with radiation therapy |
| EP2281885A1 (en) * | 2003-08-27 | 2011-02-09 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
| WO2005072772A1 (en) | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Pharmaceutical compositions |
| WO2005087808A2 (en) | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Growth factor binding constructs materials and methods |
| US20050261243A1 (en) | 2004-04-21 | 2005-11-24 | Peyman Gholam A | Antiprostaglandins for the treatment of ocular pathologies |
| CN100361710C (zh) | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用 |
| JP4680997B2 (ja) | 2004-06-08 | 2011-05-11 | ツェンドゥー カンホン バイオテクノロジーズ カンパニー リミテッド | 血管新生を阻害するキメラタンパク質およびその利用 |
| CN1304427C (zh) | 2004-06-08 | 2007-03-14 | 成都康弘生物科技有限公司 | 抑制血管新生的融合蛋白质及其用途 |
| JP2008502738A (ja) | 2004-06-10 | 2008-01-31 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用 |
| EP1755645A2 (en) | 2004-06-18 | 2007-02-28 | Regeneron Pharmaceuticals, Inc. | Vegf inhibitors for the treatment of malignant pleural effusion |
| US20060008415A1 (en) | 2004-06-25 | 2006-01-12 | Protein Design Labs, Inc. | Stable liquid and lyophilized formulation of proteins |
| CN1997386B (zh) | 2004-07-30 | 2012-05-30 | 瑞泽恩制药公司 | 通过阻断vegf介导的活性来治疗i型糖尿病的方法 |
| EP1778723B1 (en) | 2004-08-17 | 2012-11-14 | Regeneron Pharmaceuticals, Inc. | Il-1 antagonist formulations |
| WO2006043965A1 (en) | 2004-10-14 | 2006-04-27 | Allergan, Inc. | Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods |
| NZ590132A (en) | 2004-10-21 | 2012-03-30 | Genentech Inc | Dosage regime for treating intraocular neovascular diseases with VEGF |
| US7303748B2 (en) | 2005-02-02 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a VEGF inhibitor |
| ES2633574T3 (es) | 2005-03-25 | 2017-09-22 | Regeneron Pharmaceuticals, Inc. | Formulaciones de antagonistas de VEGF |
| JP2008543839A (ja) | 2005-06-14 | 2008-12-04 | アムジェン インコーポレーテッド | 自己緩衝タンパク質製剤 |
| CN100502945C (zh) | 2006-03-31 | 2009-06-24 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在治疗眼睛疾病中的应用 |
| CN100567325C (zh) | 2006-03-31 | 2009-12-09 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白及其在制备治疗眼睛疾病的药物中的应用 |
| US8216575B2 (en) | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
| PT2944306T (pt) | 2006-06-16 | 2021-02-15 | Regeneron Pharma | Formulações antagonistas de vegf adequadas para administração intravitreal |
| US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| US11078262B2 (en) | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| US20090202855A1 (en) | 2008-01-09 | 2009-08-13 | Saxton David M | Porous sliding bearing and method of construction thereof |
| WO2010125416A1 (en) | 2009-04-27 | 2010-11-04 | Raouf Rekik | Drug delivery to the anterior and posterior segments of the eye |
| CN102233132B (zh) | 2010-04-28 | 2013-10-23 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在制备抑制眼表新生血管生长的药物中的应用 |
| CN102380096B (zh) | 2010-08-31 | 2014-04-30 | 成都康弘生物科技有限公司 | 一种含有抑制血管增生的融合蛋白的药物组合物及用途 |
| CN107115294B (zh) | 2012-01-19 | 2019-10-18 | 北京康弘生物医药有限公司 | 一种含有vegf拮抗剂的滴眼液 |
| JOP20200175A1 (ar) | 2012-07-03 | 2017-06-16 | Novartis Ag | حقنة |
| JP6071099B1 (ja) | 2014-01-25 | 2017-02-01 | ツェンドゥー カンホン バイオテクノロジーズ カンパニー リミテッド | 血管の新生又は成長を抑制する融合タンパク質及びその用途 |
| US20160144025A1 (en) | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| AU2017213103B2 (en) | 2016-01-26 | 2022-08-11 | Formycon Ag | Liquid formulation of a VEGF antagonist |
| JP7116059B2 (ja) | 2016-11-21 | 2022-08-09 | ジャスト－エヴォテック バイオロジックス、インコーポレイテッド | アフリベルセプト製剤及びその使用 |
| KR101861163B1 (ko) | 2017-04-26 | 2018-05-25 | 삼천당제약주식회사 | 안과용 약학 조성물 |
| CA3189025A1 (en) | 2017-12-22 | 2019-06-27 | Samsung Bioepis Co., Ltd. | Liquid composition comprising vegf antagonist |
-
2007
- 2007-06-14 PT PT151699360T patent/PT2944306T/pt unknown
- 2007-06-14 CN CN201410707259.XA patent/CN104434770A/zh active Pending
- 2007-06-14 ES ES11157965T patent/ES2406764T3/es active Active
- 2007-06-14 EP EP15169936.0A patent/EP2944306B1/en active Active
- 2007-06-14 SI SI200731264T patent/SI2364691T1/sl unknown
- 2007-06-14 PL PL11157965T patent/PL2364691T3/pl unknown
- 2007-06-14 AU AU2007261536A patent/AU2007261536C1/en active Active
- 2007-06-14 BR BRPI0713749A patent/BRPI0713749B8/pt active Search and Examination
- 2007-06-14 RU RU2009101226A patent/RU2432155C3/ru active
- 2007-06-14 WO PCT/US2007/014085 patent/WO2007149334A2/en not_active Ceased
- 2007-06-14 US US11/818,463 patent/US7608261B2/en active Active
- 2007-06-14 HU HUE11157965A patent/HUE018715T2/hu unknown
- 2007-06-14 HU HUE15169936A patent/HUE053612T2/hu unknown
- 2007-06-14 EP EP07809593A patent/EP2029103A2/en not_active Withdrawn
- 2007-06-14 KR KR1020087029933A patent/KR101406811B1/ko active Active
- 2007-06-14 DK DK11157965.2T patent/DK2364691T3/da active
- 2007-06-14 CA CA2654510A patent/CA2654510C/en active Active
- 2007-06-14 EP EP11157965.2A patent/EP2364691B1/en active Active
- 2007-06-14 JP JP2009515517A patent/JP5216002B2/ja active Active
- 2007-06-14 ES ES15169936T patent/ES2861898T3/es active Active
- 2007-06-14 PT PT111579652T patent/PT2364691E/pt unknown
- 2007-06-14 DK DK15169936.0T patent/DK2944306T3/da active
- 2007-06-14 LT LTEP15169936.0T patent/LT2944306T/lt unknown
- 2007-06-14 PL PL15169936T patent/PL2944306T3/pl unknown
- 2007-06-14 SI SI200732171T patent/SI2944306T1/sl unknown
- 2007-06-14 CN CNA2007800225554A patent/CN101478949A/zh active Pending
- 2007-06-14 EP EP20178021.0A patent/EP3753548A1/en active Pending
- 2007-06-14 MX MX2008016124A patent/MX2008016124A/es active IP Right Grant
-
2008
- 2008-11-18 ZA ZA2008/09827A patent/ZA200809827B/en unknown
- 2008-12-08 IL IL195788A patent/IL195788A/en active IP Right Grant
-
2009
- 2009-09-16 US US12/560,885 patent/US7807164B2/en active Active
-
2010
- 2010-07-09 US US12/833,417 patent/US8092803B2/en active Active
-
2011
- 2011-12-19 US US13/329,770 patent/US8481046B2/en active Active
-
2013
- 2013-03-01 JP JP2013040234A patent/JP5597271B2/ja active Active
- 2013-06-11 US US13/914,996 patent/US8802107B2/en active Active
- 2013-07-15 CY CY20131100595T patent/CY1114244T1/el unknown
-
2014
- 2014-07-14 US US14/330,096 patent/US9340594B2/en active Active
-
2015
- 2015-06-02 HK HK15105252.5A patent/HK1204580A1/xx unknown
-
2016
- 2016-04-11 US US15/095,606 patent/US9914763B2/en active Active
- 2016-05-11 US US15/151,776 patent/US9580489B2/en active Active
-
2018
- 2018-01-24 US US15/879,294 patent/US10400025B2/en active Active
- 2018-10-12 US US16/159,269 patent/US10464992B2/en active Active
-
2019
- 2019-09-25 US US16/582,486 patent/US11066458B2/en active Active
-
2020
- 2020-01-10 US US16/739,559 patent/US11084865B2/en active Active
-
2021
- 2021-03-22 CY CY20211100247T patent/CY1124265T1/el unknown
- 2021-06-15 US US17/348,438 patent/US11732024B2/en active Active
-
2023
- 2023-06-29 US US18/344,786 patent/US20230374108A1/en not_active Abandoned
-
2024
- 2024-10-23 US US18/924,707 patent/US12331099B2/en active Active
-
2025
- 2025-04-11 US US19/176,527 patent/US20250257118A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009540001A5 (enExample) | ||
| RU2009101226A (ru) | Составы антагониста vegf, подходящие для интравитреального введения | |
| JP2013079270A5 (enExample) | ||
| JP4789698B2 (ja) | 因子ｉｘ用処方 | |
| CN101141975B (zh) | Vegf拮抗剂制剂 | |
| RU2011127913A (ru) | Составы, содержащие антитела | |
| US20190388348A1 (en) | Compositions and methods for treating cardiovascular and pulmonary diseases with apelin | |
| JP2012121894A (ja) | Ｉｌ−１アンタゴニスト製剤 | |
| JP2005526084A5 (enExample) | ||
| JP2012515221A5 (enExample) | ||
| JP2015231997A5 (enExample) | ||
| JP2006257099A (ja) | 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方 | |
| JP2016520075A5 (enExample) | ||
| JP2016533345A5 (enExample) | ||
| JP2017510585A5 (enExample) | ||
| JP2008510716A5 (enExample) | ||
| ES2595160T3 (es) | Uso combinado de un glucosaminoglicano sulfatado y una hialuronidasa para mejorar la biodisponibilidad del Factor VIII | |
| US20140148387A1 (en) | Freeze-dried recombinant human bone morphogenetic protein-2 preparation | |
| KR101710471B1 (ko) | 건조한 트랜스글루타미나제 조성물 | |
| ES2449044T3 (es) | Procedimiento de administración de fVIII sin dominio B porcino | |
| IL316880A (en) | Freeze-dried RNA composition (lyophilization) | |
| EP4598572A1 (en) | Novel vsv virus formulations | |
| NZ733837B2 (en) | Pharmaceutical composition comprising plasminogen and uses thereof |